cover
Eli Lilly and Co said on Wednesday that its combination antibody therapy to fight COVID-19 reduced the risk of hospitalization and death by 87% in a study of more than 750 high-risk COVID-19 patients.

No comments yet, Let's kick-start a discussion.

Please Login or Register to Comment.